Quantcast

Latest Halozyme Therapeutics Inc. Stories

2014-02-27 16:28:39

SAN DIEGO, Feb. 27, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2013. Financial highlights for the fourth quarter include revenues of $12.5 million and a net loss of $22.0 million, or $0.19 per share. This compares to revenues of $21.8 million and a net loss of $4.4 million, or $0.04 per share, for the fourth quarter of 2012. Financial highlights for the full year 2013 include...

2014-02-25 16:30:00

SAN DIEGO, Feb. 25, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Cowen and Company 34(th) Annual Healthcare Conference in Boston, MA on Tuesday, March 4, 2014 at 9:20 a.m. ET/6:20 a.m. PT. David Ramsay, Chief Financial Officer, will provide a corporate overview. (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO) The presentation will be webcast through the "Investors" section of Halozyme's corporate website at...

2014-02-20 16:26:08

SAN DIEGO, Feb. 20, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter and full year 2013 on Thursday, February 27, 2014 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the fourth quarter and year-ended December 31, 2013....

2014-02-10 16:27:18

SAN DIEGO, Feb. 10, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today the closing of its previously announced public offering of 8,846,153 shares of common stock, including 1,153,846 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $13.00 per share. Halozyme's net proceeds from this offering are expected to be approximately $107.8 million, after deducting the underwriting...

2014-02-04 20:24:04

SAN DIEGO, Feb. 4, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today the pricing of its previously announced underwritten public offering of 7,692,307 shares of its common stock at a public offering price of $13.00 per share. All of the shares in the offering are being sold by Halozyme. The offering is expected to close on February 10, 2014, subject to customary closing conditions. In addition, Halozyme has granted the underwriters a 30-day option to...

2014-02-03 16:25:14

SAN DIEGO, Feb. 3, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock. All of the shares in the offering are to be sold by Halozyme. Halozyme intends to grant the underwriters a 30-day option to purchase up to $15,000,000 of additional shares. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the...

2014-01-24 12:23:26

SAN DIEGO, Jan. 24, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approve Roche's subcutaneous (SC) formulation of MabThera(®) (rituximab) using Halozyme's recombinant human hyaluronidase (rHuPH20) for the treatment of patients with common forms of non-Hodgkin lymphoma (NHL). (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)...

2014-01-13 08:27:20

SAN DIEGO, Jan. 13, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today provided an update on the anticipated milestones for its product development programs in 2014. (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO) "Halozyme is poised for a pivotal year in 2014," stated Dr. Helen Torley, President and Chief Executive Officer. "With multiple collaboration products advancing to commercialization stage, our focus is now on advancing and unlocking the value of...

2014-01-09 16:25:28

SAN DIEGO, Jan. 9, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2014 at 10:00 a.m. PT / 1:00 p.m. ET. Helen Torley, M.B. Ch. B., M.R.C.P., President and Chief Executive Officer of Halozyme Therapeutics, will provide a corporate overview. (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO) The presentation will be webcast through the...

2014-01-06 08:27:42

SAN DIEGO, Jan. 6, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced it secured an additional $20 million loan from Oxford Finance and Silicon Valley Bank. On December 27, 2013, Halozyme entered into an Amended and Restated Loan and Security Agreement, extending the original $30 million term loan and providing for an additional $20 million term loan, bringing the total loan balance to $50 million. The term loan was fully drawn at close on December 27,...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related